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Summary
We demonstrate a physiological role for tumstatin, a cleavage fragment of the 3 chain of type IV collagen (Col IV3),
which is present in the circulation. Mice with a genetic deletion of Col IV3 show accelerated tumor growth associated
with enhanced pathological angiogenesis, while angiogenesis associated with development and tissue repair are unaffected.
Supplementing Col IV3-deficient mice with recombinant tumstatin to a normal physiological concentration abolishes the
increased rate of tumor growth. The suppressive effects of tumstatin require V3 integrin expressed on pathological,
but not on physiological, angiogenic blood vessels. Mice deficient in matrix metalloproteinase-9, which cleaves tumstatin
efficiently from Col IV3, have decreased circulating tumstatin and accelerated growth of tumor. These results indicate
that MMP-generated fragments of basement membrane collagen can have endogenous function as integrin-mediated
suppressors of pathologic angiogenesis and tumor growth.
Introduction quential VBM changes that result in exposure of endothelial
cells to different isoforms, degradation products, and molecular
Vascular basement membranes (VBM) are specialized extracel- structures of VBM molecules in a short period of time (Carmeliet
lular matrices that provide mechanical support for endothelial and Jain, 2000; Czubayko et al., 1997; Eliceiri et al., 1999;
cells (Colorado et al., 2000; Madri, 1997; Paulsson, 1992; Timpl, Ferrara, 2000; Folkman, 2001; Folkman and Kalluri, 2003; Hana-
1996; Yurchenco and O’Rear, 1994) and influence cellular be- han and Weinberg, 2000; Kalluri, 2003; Padera et al., 2002;
havior such as differentiation and proliferation (Madri, 1997; Stacker et al., 2002).
Paulsson, 1992; Tsilibary et al., 1990), especially during the Our prevailing hypothesis is that such sequential isoform
sprouting of new capillaries. VBM organization is dependent on switching and structural changes associated with VBM can pro-
the assembly of a type IV collagen network, which is believed vide crucial angiogenic and antiangiogenic stimuli to perpetuate
to occur via the C-terminal globular non-collagenous (NC1) do- formation of new capillaries (Colorado et al., 2000; Kamphaus
main of Col IV (Kuhn, 1995; Madri, 1997; Madri and Pratt, 1986; et al., 2000; Maeshima et al., 2000a, 2000b, 2001a, 2001b,
Timpl, 1996; Tsilibary et al., 1990; Zeisberg et al., 2001; Zhang et 2002; Thyboll et al., 2002). There are six distinct gene products,
al., 1994). Inhibitors of collagen metabolism have antiangiogenic 1-6 for Col IV (Hudson et al., 1993; Prockop and Kivirikko,
1995). The distribution of the3 (IV) chain is limited to glomerularproperties, supporting the notion that basement membrane
(BM) collagen synthesis and deposition are crucial for blood BM (GBM), several BM of the cochlea, ocular BM of the anterior
lens capsule, Descemet’s membrane, ovarian and testicular BMvessel formation and survival (Maragoudakis et al., 1993, 1995;
Tsilibary et al., 1990). Once the endothelium receives signals (Frojdman et al., 1998), alveolar capillary BM (Hudson et al.,
1993; Kashtan, 1998; Polette et al., 1997), and the VBM ofto proliferate from the tumor microenvironment, it initiates se-
S I G N I F I C A N C E
Progression of cancer is dependent on neoangiogenesis. Tumor progression is likely governed by relative levels of pro- and antiangio-
genic factors—the “angiogenic balance.” Conversion of dormant in situ carcinomas into an invasive malignant phenotype is
considered to involve a shift in favor of enhanced angiogenesis potential. Influenced by oncogenes and tumor suppressor genes,
disruption of the “angiogenic check point” via increase in angiogenic factors such as VEGF or decrease in the physiological levels
of endogenous inhibitors of angiogenesis like thrombospondin-1 and tumstatin could represent an important lethal step in the
progression of cancer. Thus, genetic control of the physiological levels of endogenous inhibitors of angiogenesis might constitute a
critical last line of defense against conversion of neoplastic events into a malignant phenotype of cancer.
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several organs (Derry and Pusey, 1994; Kashtan, 1998), but is To determine if altered vascularity was the underlying mech-
anism of the increased tumor growth, we analyzed a secondabsent from epidermal and VBM in the skin (Kashtan, 1998).
During BM synthesis, turnover fragments are generated type of pathological angiogenesis in the growth factor-supple-
mented Matrigel plug assay. We observed increased angiogen-which are liberated into the circulation, raising the question as
to whether they have any physiological function (Hogemann et esis in the Col IV3/tumstatin-deficient mice, as compared to
the wild-type mice (Figure 2B). Col IV3/tumstatin-deficiental., 1984; Ortega and Werb, 2002; Standker et al., 1997). The
bioactive NC1 domain of Col IV3, called tumstatin, acts as an mice demonstrating increased rate of tumor growth had in-
creased numbers of CD31-positive blood vessels (Figure 2C).angiogenesis inhibitor, inhibiting the proliferation of capillary
endothelial cells and blood vessel formation in vitro and in vivo Recent studies have suggested that increases in the circulating
vascular endothelial growth factor receptor 2 (VEGFR2)-positive(Maeshima et al., 2000a, 2000b, 2001a, 2001b; Petitclerc et al.,
2000). Deletion mutagenesis experiments have narrowed the endothelial cells correlate directly with increase in tumor angio-
genesis and can serve as in vivo indicators of tumor angiogen-biological activity to a 25 amino acid stretch in the middle of
the molecule (Maeshima et al., 2001b). Tumstatin binds to V3 esis (Heissig et al., 2002; Lyden et al., 2001; Monestiroli et al.,
2001). Col IV3/tumstatin-deficient mice had increased circulat-integrin via a mechanism independent of the RGD-containing
amino acid sequence (Maeshima et al., 2000a). However, since ing VEGFR2-positive endothelial cells (Figure 2D).
If the regulation of angiogenesis relies on the presence ofprevious studies relied on exogenous addition of tumstatin (or
fragments of other basement membrane collagens), this raises circulating tumstatin, then exogenous addition of tumstatin to
physiological levels in the null mice should decrease the numberthe question of whether such fragments have an endogenous
physiological function. Here we provide genetic evidence sup- of blood vessels and circulating endothelial cells to the wild-
type baseline levels. Indeed, we observed suppression of tumorporting a role for tumstatin as an endogenous suppressor of
pathological angiogenesis and tumor growth. angiogenesis to wild-type levels (Figures 2C and 2D), indicating
that the lack of tumstatin domain alone is responsible for the
accelerated tumor growth in the Col IV3-deficient mice.Results
By contrast, physiological angiogenesis associated with tis-
sue repair was unaffected in the Col IV3/tumstatin-deficientMice with deletion of collagen IV 3 (tumstatin precursor)
exhibit normal pregnancy, development, and wound mice. Closure/repair in skin wounds progressed at the same
rate in the wild-type and the null mice (Figure 3A) and showedhealing, but accelerated pathologic
angiogenesis and tumor growth insignificant differences in histology and CD31-positive blood
vessels (Figures 3A and 3B). Similarly, regeneration of liver afterAngiogenesis plays an important role during pregnancy and
embryonic development. Tumstatin, which has a circulating partial hepatectomy was similar in the wild-type and null mice.
The rates of regeneration assessed by the proliferation indexphysiological concentration of about 336  28 ng/ml in normal
mice, was absent in mice deficient in 3 chain of Col IV, the of the liver, as determined by BrdU staining (Figure 3C), and
angiogenesis, assessed by the number of von Willebrand Factorprecursor for tumstatin (Figures 1A and 1B), without altering the
litter size, pregnancy, or development (Figures 1C and 1D). In (vWF)-positive blood vessels (Figure 3D), were similar in the
wild-type and null mice.the present study, we refer to the Col IV3-deficient mice (An-
drews et al., 2002; Cosgrove et al., 1996; Miner and Sanes,
1996) as also tumstatin deficient. After week 20, these mice on Antiangiogenic activity of tumstatin
requires V3 integrinC57BL/6 background develop kidney dysfunction associated
with GBM abnormalities and inflammation and die at around Tumstatin binds to V3 integrin in a vitronectin/RGD se-
quence-independent manner (Maeshima et al., 2000a). If theweek 40 due to renal failure resulting from the absence of Col
IV3 in the GBM (Andrews et al., 2002; data not shown). antiangiogenic action of tumstatin is mediated through this re-
ceptor, then cells and mice lacking V3 integrin should notNext, we evaluated tumor-associated pathological angio-
genesis in Col IV3/tumstatin-deficient mice on a C57BL/6 respond to it. Tumstatin or active derivative T7 peptide (Mae-
shima et al., 2001b) at 1 M, which has been shown previouslybackground. Tumors from Lewis lung carcinoma (LLC) cells
(106) placed on the backs of mice appeared at about 7 days to achieve maximum inhibition of endothelial cell proliferation
(Maeshima et al., 2000b), significantly inhibited proliferation ofand grew at the same rate in wild-type and Col IV3/tumstatin-
deficient mice until they reached about 500 mm3 of tumor vol- wild-type mouse lung endothelial cells (MLEC) in response to
growth factor stimulation, while proliferation of 3 integrin nullume (Figure 2A). Consistently, from this size, the tumors on Col
IV3/tumstatin-deficient mice grew at a faster rate and, by day MLEC was unaffected (Figure 4A). By contrast, mouse endo-
statin (the NC1 domain of 1 chain of collagen XVIII) was equally26, the tumors on the Col IV3/tumstatin-deficient mice were
more than twice the size of wild-type tumors (Figure 2A). Admin- effective in inhibiting the proliferation of both wild-type and 3
integrin null MLEC (Figure 4A).istration of 300 ng of recombinant human tumstatin, which has
a half-life of about 20 hr in mice (data not shown), daily to the Neovascularization of growth factor-supplemented Matrigel
plugs in mice is associated with significant expression of 3Col IV3/tumstatin-deficient mice with 500 mm3 LLC tumors,
decreased tumor growth to wild-type levels (Figure 2A). These integrin (Figure 4B). We next evaluated the antiangiogenic ac-
tivity of tumstatin in vivo in the Matrigel plug assay system inexperiments demonstrate that restoration of physiological levels
of tumstatin in Col IV3/tumstatin-deficient mice suppresses wild-type and 3 integrin-deficient mice on the C57BL/6 back-
ground. Both tumstatin and endostatin significantly inhibitedthe accelerated growth of tumors (Figure 2A). Similar results
were obtained with syngeneic B16F10 melanoma and T241 VEGF-induced neovascularization of the plugs in the wild-type
mice (Figure 4C). However, while endostatin significantly inhib-fibrosarcoma tumors (O’Reilly et al., 1997) in Col IV3/tumstatin-
deficient mice (data not shown). ited blood vessels in the Matrigel plugs implanted in the 3
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Figure 1. Tumstatin and Col IV3/tumstatin/ mice
A: Schematic illustration of the type IV collagen 3 chain and tumstatin. Tumstatin (solid shading) is indicated in relation to type IV collagen 3 chain.
B: Circulating levels of tumstatin in mouse blood. The plasma from ten wild-type (T/) and ten Col IV3/tumstatin/ (T/) mice was examined using direct
ELISA with anti-tumstatin antibody. Standard curve was calculated using recombinant tumstatin protein and anti-tumstatin antibody. ** indicates p  0.01;
compared to T/. The results are shown as the mean  SEM.
C and D: Litter size and development of Col IV3/tumstatin/ mice. To evaluate litter size at birth, an average number of eight separate litters delivered
by T/ and T/ parents was counted. In order to evaluate early development of pups, a 6 week survival rate for eight separate litters from both groups
was calculated. The results are shown as the mean  SD.
integrin-deficient mice, tumstatin had an insignificant effect (Fig- this issue, we assessed the vascular expression of 1 and 3
integrin in tumors starting from a size of 100 mm3 to 5000 mm3.ure 4C). These data suggest that tumstatin action in vivo is likely
mediated by V3 integrins. Interestingly, our results indicate that while 1 was expressed
in about 80% of the blood vessels even in tumors as small
as 100 mm3, 3 integrin was expressed in only about 8% ofTumstatin functions as an inhibitor of tumor-associated
pathological angiogenesis, while having no effect capillaries at this stage (Figure 6). The 3 expression increased
to about 40% of the blood vessels by the time the tumorson physiological angiogenesis due to differential
expression of 3 integrin reached 500 mm3 and remained at that level, no matter how
How can tumstatin function as an inhibitor of tumor-associated large the tumor (Figure 6). Expression of 1 integrin at this stage
pathological angiogenesis, while having no effect on physiologi- continued to be detected in 80% of the blood vessels. Since
cal angiogenesis associated with repair and regeneration of skin significant 3 integrin expression on the vasculature was seen
and liver? Our experiments suggest that tumstatin depends on only beginning at the size of 500 mm3 and tumstatin does not
V3 integrin for inhibition of tumor-associated pathological induce negative regulation when the tumors are smaller than
angiogenesis. We detected V3 integrin on about 40% of the 500 mm3 (Figures 2, 4, 5 and 6), the vascular expression pattern
blood vessels and small capillaries in proliferating tumors; how- of 3 integrin provides a possible explanation for the lack of
ever, we did not detect it in the blood vessels of healing skin tumor growth difference between the wild-type and Col IV3/
wounds or regenerating livers (Figure 5A). In contrast,1 integrin tumstatin-deficient mice until the tumors reach the size of
was detected on all blood vessels and capillaries associated 500 mm3.
with tumor growth, healing wounds, and regenerating skin liver
(Figure 5B). Such differences in V3 integrin levels may explain Degradation of basement membrane type IV collagen
by MMP-9 generates tumstatinthe lack of tumstatin effect on repair and regeneration, while
targeting tumor vasculature (Figure 3). How is tumstatin generated from BM collagen? BM-degrading
MMPs that degrade Col IV could potentially liberate fragmentsWhy do tumors grow faster in the Col IV3/tumstatin-defi-
cient mice only after they reach a size of 500 mm3? To address such as NC1 domains of Col IV (Kalluri, 2003; McCawley and
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Figure 2. Tumor burden studies in Col IV3/tumstatin-deficient mice
A: LLC tumor growth in Col IV3/tumstatin/ mice. Twelve age- and sex-matched Col IV3/tumstatin/ mice and six wild-type mice were used in this
experiment. Recombinant tumstatin protein was intravenously injected into seven Col IV3/tumstatin/ mice daily (300 ng) for 8 days starting at day 18
in sterile PBS, while only PBS was injected into the other five Col IV3/tumstatin/ mice. Data are representative of four such independent experiments.
The results are shown as the mean  SEM. ** indicates p  0.01; * indicates p  0.05; compared to Col IV3/tumstatin/ mice without injection. Scale
bar: 1 cm.
B: Matrigel plug assay in Col IV3/tumstatin/ mice. Sections of each Matrigel plug were stained with HE and the numbers of blood vessels (arrow) in ten
fields at 200 magnification were counted. Each column represents the mean  SEM of six mice in each group. * indicates p  0.05; compared to Col
IV3/tumstatin/ mice. Scale bar: 50 m.
C: Blood vessel quantification in LLC tumors. Frozen sections (4 m) from tumor tissue were stained with anti-CD31 antibody, and the number of CD31-
positive blood vessels (arrow) was counted. The results are shown as the mean  SEM. ** indicates p  0.01; compared to Col IV3/tumstatin/ mice.
Scale bar: 50 m.
D: VEGF receptor 2 (VEGFR2)-positive circulating endothelial cells in mice. The blood cells from peripheral blood attached to the slide were stained with
anti-VEGFR2 antibody, and the number of positive cells (arrow) was counted. The results are shown as the mean  SEM. ** indicates p  0.01; compared
to Col IV3/tumstatin/ mice. Scale bar: 50 m.
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Figure 3. Repair-associated angiogenesis in Col IV3/tumstatin-deficient mice
A: Skin wound healing in Col IV3/tumstatin/ mice. One centimeter diameter skin wounds were induced in five wild-type (T/), five Col IV3/tumstatin/
(T/), and five Col IV3/tumstatin/ (T/) mice. The areas were measured periodically as indicated and the ratio in relation to the original wound size at
day 0 was calculated at each time point. There was insignificant difference in the wound healing among the groups at all time points. The results are
shown as the mean  SEM. The PAS-stained wound areas at day 10 are shown here. Scale bar: 50 m.
B: Quantification of blood vessels in the skin. Frozen sections (4 m) were stained with the anti-CD31 antibody and the numbers of CD31-positive blood
vessels (arrow) were counted. The results are shown as the mean  SEM. Scale bar: 50 m.
C and D: Liver regeneration in Col IV3/tumstatin/ mice. Seventy percent of the liver was removed in T/, T/, and T/ mice with five mice per group.
The proliferating hepatic cells were double-stained with BrdU and DAPI (arrow). Frozen sections (4 m) from liver tissue were stained with anti-von Willebrand
Factor (vWF) antibody to evaluate blood vessels (arrow). The results are shown as the mean  SEM. Scale bar: 50 m.
Matrisian, 2001). We found that active MMP-9 was most effec- pared with 350  24 ng/ml in the wild-type mice (p  0.01).
These results suggest that normal physiological turnover of BMtive in liberating C-terminal NC1 globular domains in dimeric and
monomeric forms, detected in the supernatant by polyclonal by MMPs, especially MMP-9, contributes to the circulating lev-
els of tumstatin.tumstatin antibody, from the GBM which is rich in the Col IV3
chain (Frojdman et al., 1998; Gunwar et al., 1991; Kalluri and
Cosgrove, 2000) (Figures 7A and 7B). Three other BM-degrading Restoration of tumstatin levels inhibits the increased
tumor growth rate in MMP-9-deficient miceproteinases, MMP-2, MMP-3, and MMP-13, also released tum-
statin, but were significantly less efficient (data not shown). MMP-9 What circulating levels of tumstatin are required to inhibit tumor
growth? The growth of LLC tumors implanted into wild-typeis significantly less efficient in liberating arresten and canstatin
from BMs, when compared to tumstatin (data not shown). mice and MMP-9-deficient mice on a C57BL/6 background was
similar until the tumors reached 500 mm3, but after that, theMice deficient in MMP-9 had significantly decreased circu-
lating blood concentrations of tumstatin; 141  21 ng/ml, com- tumors on MMP-9-deficient mice exhibited accelerated growth
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Figure 4. Tumstatin activity in 3 integrin-defi-
cient mice
A: Proliferation assay in 3 integrin/ endothelial
cells. MLEC were isolated from wild-type (3/)
and 3 integrin/ (3/) mice as previously de-
scribed (Maeshima et al., 2002). Proliferation was
assessed by [3H]-thymidine incorporation. All
groups represent triplicate analyses. The results
are shown as the mean  SEM. ** indicates p 
0.01; compared to control cells.
B: Expression of 1 and 3 integrins in blood ves-
sels of Matrigel plug. 1 and 3 integrin-positive
blood vessels are indicated with arrows. Scale
bar: 50 m.
C: Matrigel plug assay in 3 integrin/mice. Sec-
tions of each Matrigel plug were stained with HE
and the number of blood vessels (arrow) was
counted. Each column represents the mean 
SEM of 2–4 mice in each group. Data are repre-
sentative of two independent Matrigel plug ex-
periments. ** indicates p  0.01; compared to
each control groups. † indicates p  0.05; com-
pared to the control group in 3 integrin/ mice.
Scale bar: 50 m.
(Figure 8A). Injection of 200 ng of recombinant human tumstatin strated that tumstatin, a BM Col IV3 chain-derived NC1 do-
main, can be detected in the circulation of normal mice andintravenously daily for 14 days into MMP-9-deficient mice with
established tumors raised the concentration of tumstatin to the functions as an endogenous regulator of pathologic angiogen-
esis and that the activity of tumstatin is dependent on V3normal levels of about 342  13 ng/ml (data not shown) and
resulted in a retarded rate of growth to match the wild-type integrin and the ECM-degrading enzyme, MMP-9.
The Col IV3 chain is localized to many VBM and is mosttumor growth (Figure 8A, inset). This deceleration of tumor
growth was accompanied by decreased numbers of CD31- abundant in the GBM of the kidney and the BM of the testis
(Frojdman et al., 1998; Hudson et al., 1993; Kahsai et al., 1997).positive blood vessels and VEGFR2-positive circulating endo-
thelial cells (Figures 8B and 8C). Collectively, these results sug- It is likely that physiological turnover of GBM and other BM
mediated by ECM-degrading MMPs contributes to the circulat-gest that the increase in LLC tumor growth in MMP-9-deficient
mice was due to decreased physiological levels of tumstatin. ing physiological levels of tumstatin. Col IV3 chain-deficient
mice do not have circulating tumstatin, and syngeneic LLC tu-
mors larger than 500 mm3 on these mice grew at more thanDiscussion
twice the rate of tumors on wild-type mice. This difference in
growth could be restored to wild-type levels when the null miceBasement collagens in their native molecular structure form a
scaffold for cell homeostasis. In this study, we have demon- were provided with physiological concentrations of tumstatin in
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Figure 5. Expression of 3 and 1 integrins in tumors, healing skin wound,
and regenerating livers
A: Immunohistochemical staining with anti-3 integrin (3) antibody and
CD31 or vWF was performed to assess localization of 3 integrin in blood
vessels. Anti-CD31 antibody was used for the tumor and skin tissues and
anti-vWF antibody was used for the liver tissue. 3 integrin-positive blood
vessels (merge) are indicated with arrows. Scale bar: 50 m.
B: 1 integrin expression in the tumor, skin wound, and regenerating liver
tissues. 1 integrin-positive blood vessels (merge) are shown here. 1 integ-
rin-positive vessels are indicated with arrows. Scale bar: 50 m.
recombinant form. These results suggest that the acceleration
of tumor growth in the null mice is not due to the absence of
3 (IV) chain, but is likely due the lack of the tumstatin domain.
Our study distinguishes the physiological role of tumstatin from Figure 6. Expression of 3 and 1 integrins in tumors of various sizes
its potential pharmacological applications. Providing tumstatin A: Immunohistochemical staining with anti-3 integrin (3) antibody and
(300 ng/day, i.v.) to the null mice slowed the tumor growth to CD31 was performed to assess localization of 3 integrin in the tumor blood
vessels with volumes of 0.1, 0.5 and 3.0 cm3 in wild-type mice. 3 integrin-the wild-type level, but did not cause regression or inhibition
positive blood vessels (merge) are indicated with arrows. Scale bar: 50 m.of tumor growth. The pharmacological doses needed to achieve
B: 1 integrin expression in tumors with volumes of 0.1, 0.5, and 3.0 cm3.inhibition of LLC tumor growth are much higher, in the range
1 integrin-positive vessels (merge) are indicated with arrows. Scale bar:
of 5–15 g/day, i.v. (data not shown). Further studies are 50 m.
C: Quantification of 1/3 integrin-positive blood vessels in the tumor. Therequired to understand what mechanisms drive the switch be-
ratio of 3 integrin-positive blood vessels to CD31-positive vessels (open bar)tween the physiological and pharmacological functions of tum-
was calculated in the tumors with various volumes. As a control, the ratiostatin.
of 1 integrin-positive blood vessels to vWF-positive vessels (closed bar) was
An interesting insight into the physiological role of tumstatin also calculated. ** indicates p  0.01; compared to 3 integrin-positive
in the suppression of tumstatin can be made from the observa- blood vessels in 0.1 cm3 of tumor. †† indicates p0.01; compared to 3
integrin-positive blood vessels in 0.2 cm3 of tumor.tion that, until the tumors reach 500 mm3, the difference in tumor
growth between the wild-type mice and Col IV3/tumstatin-
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the entire antiangiogenic arsenal including tumstatin is required
for the control of tumor growth.
We previously implicated V3 integrin as a putative recep-
tor for tumstatin and the binding between them (Maeshima et al.,
2000a, 2001a, 2001b, 2002) is independent of RGD sequence,
vitronectin, and fibronectin binding. In the present study, we
used genetic experiments with 3-deficient mice to demon-
strate that V3 integrin mediates tumstatin action. Tumors also
grow faster in3-deficient mice than in wild-type mice (Reynolds
et al., 2002). Collectively, these observations strongly suggest
a role for V3 integrin as a negative regulator of angiogenesis
(Hynes, 2002a; Hynes et al., 2002b; Kalluri, 2002; Maeshima et
al., 2001a).
Our experiments suggest that tumor angiogenesis, but not
angiogenesis associated with the repair of skin wound and re-
generation of liver, is associated with robust expression of 3
integrins, including V3 integrin. This is likely the explanation
for the lack of difference on the skin wound repair and liver
regeneration in the Col IV3/tumstatin-deficient mice and also
in pharmacological studies with recombinant human tumstatin
(data not shown). Both Col IV3/tumstatin-deficient mice and
3 integrin-deficient mice on a C57BL/6 background do not
exhibit developmental angiogenesis defects (Andrews et al.,
2002; Cosgrove et al., 1996; Hodivala-Dilke et al., 1999), sug-
gesting that 3 integrin and tumstatin may not be essential for
the regulation of developmental angiogenesis.
MMP-9 has been implicated in the degradation of type IV
collagen present in the BM (Egeblad and Werb, 2002; McCawley
and Matrisian, 2001), and fragments of Col IV and laminin have
been detected in the serum of normal individuals and cancer
patients (Gabrielli et al., 1988; Yudoh et al., 1994). Tumstatin is
a proteolytic product that has to be liberated from the parent
Col IV3 chain. MMP-9 was the most effective enzyme in the
generation of tumstatin domain from BM and type IV collagen
Figure 7. Degradation of basement membrane preparation by active preparations from the human kidney, testis, and placenta and
MMP-9
amnion. We demonstrated that mice deficient in MMP-9 have
A: Western blot of BM degraded by MMP-9. MMP-9 enzyme was added to lower circulating levels of tumstatin, and that this results in
GBM at a 1:100; enzyme:substrate ratio, and the generation of tumstatin
increased tumor growth. The accelerated tumor growth can bewas detected by SDS-PAGE and immunoblotting using anti-tumstatin anti-
restored to wild-type levels by supplementing the null mice withbody. To establish MMP specificity in generation of tumstatin, 20 mM EDTA
was added to the MMP/GBM mixture to inactivate MMP. The expected the missing physiological concentration of tumstatin. Moreover,
dimer (black arrow) and monomer (white arrow) of tumstatin are indicated. Col IV is elevated in the tumor tissue and also in the GBM of
Monomers and dimers of type IV collagen NC1 domain have been pre-
MMP-9-deficient mice (data not shown). Such increased accu-viously described (Kalluri et al., 1997b).
mulation is likely due to reduced Col IV turnover in the mice.B: Quantification of tumstatin production by MMP-9 by ELISA. MMP-9 enzyme
was added to 1 mg of GBM, and the production of soluble tumstatin in the These results provide further evidence for the endogenous tu-
supernatant was analyzed by ELISA using anti-tumstatin antibody. The results mor-suppressive action of tumstatin.
are shown as the mean SD. ** indicates p 0.01; compared to the control However, MMP-9 has also been implicated as a positive
group without enzyme.
regulator of the angiogenic switch, which leads to early stage
tumor differences resulting in lower tumor size and volume (Ber-
gers et al., 2000). But, in the same mice at a later stage, the
tumor size and volume catch up with the wild-type levels, sug-
deficient mice is insignificant. Our results suggest that lack of
gesting an acceleration of tumor growth in the absence of
significant vascular expression of 3 integrin until the tumors MMP-9, as observed in the present study (personal communica-
reach 500 mm3 is a likely explanation for the insignificant differ- tion, G. Bergers and D. Hanahan). In this regard, Pozzi et al.
ence in the growth of tumor in the absence of tumstatin before recently demonstrated that pharmacological inhibition of
tumors reach 500 mm3. Alternatively, it is possible that during MMP-9 in mice results in acceleration of tumor growth, further
the early growth phase of the tumors, absence of tumstatin can supporting our observation (Pozzi et al., 2000, 2002). Thus,
be compensated by other inhibitors of angiogenesis, such as MMP-9 has opposing actions on neoplasia at different stages of
thrombospondin-1, angiostatin, and endostatin (Hawighorst et tumor progression. While it may mediate the angiogenic switch
al., 2001; O’Reilly et al., 1994, 1997; Rodriguez-Manzaneque leading to the initial burst of tumor growth, it also restrains tumor
et al., 2001; Volpert et al., 2002). But once the tumor reaches development by generating endogenous inhibitors of angiogen-
esis such as tumstatin. After the angiogenic switch has beena critical size and 3 integrin expression increases significantly,
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Figure 8. Enhanced tumor growth in MMP-9-deficient mice
A: LLC tumor growth in MMP-9/ mice. Eight age- and sex-matched MMP-9/ mice and ten wild-type mice were used for this experiment. While at the
very early stages (between 50 mm3 and 100 mm3), MMP-9/ tumors grew slightly slower; after that (especially 	500 mm3), they grew at a much faster rate
compared to wild-type tumors. Circulating levels of tumstatin were 350 ng/ml in wild-type mice compared to 141 ng/ml in the MMP-9/ mice. When the
tumor volume reached 2.0 cm3, tumstatin was intravenously injected into four MMP-9/ mice (200 ng/day) for 14 days. Their tumor growth was compared
to wild-type tumors starting at a size of 2.0 cm3. For these experiments, the tumors in the wild-type and MMP-9/ mice were grown until the both sets of
tumors reached 2.0 cm3 (the wild-type tumors take 28 days to reach this size, while tumors in MMP-9/ mice take 21 days to reach this size). The accelerated
tumor growth in MMP-9/ mice was suppressed by exogenous tumstatin, when compared with wild-type mice. The results are shown as the mean  SEM.
** indicates p  0.01; * indicates p  0.05; compared to wild-type mice. Scale bar: 1 cm.
B: Blood vessel quantification in LLC tumors. Frozen sections (4 m) from tumor tissue were stained with anti-CD31 antibody and the number of CD31-
positive blood vessels (arrow) counted. The results are shown as the mean  SEM. ** indicates p  0.01; compared to MMP-9/ mice. Scale bar: 50 m.
C: VEGFR2-positive circulating endothelial cells in mice. Cells from peripheral blood were stained with VEGFR2 antibody and the numbers of positive cells
(arrow) were counted. The results are shown as the mean  SEM. ** indicates p  0.01; compared to MMP-9/ mice. Scale bar: 50 m.
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In vivo tumor studiesachieved by MMP-9, the degradation products resulting from
Age- and sex-matched Col IV3/tumstatin/, MMP-9/, and wild-typedigestion of BM by the increased amount of MMP-9 negatively
(C57BL/6) mice were used for these studies. All mouse studies were reviewedinfluence the growth of tumors. Therefore, the two opposite
and approved by the animal care and use committee of Beth Israel Deacon-
properties of MMP-9 are integral to the overall progression of ess Medical Center. Their backs were shaved and LLC cells were injected
tumor growth. In this regard, recent clinical trial failures with subcutaneously on the backs of the mice (1  106 cells/mouse). The tumors
were measured using Vernier calipers, and the volume was calculated usingMMP inhibitors could be explained by our data, although early
a standard formula (Width2  Length  0.52) (Maeshima et al., 2000b). Forintervention of tumor growth by MMP inhibitors is still potentially
Figure 2, 12 tumstatin/ and 6 wild-type mice were used. Eighteen daysfeasible (Bramhall et al., 2002).
after the injection, Col IV3/tumstatin/ mice were divided into two groups.
What roles do the other physiological angiogenesis inhibi- Tumstatin protein was intravenously injected into seven Col IV3/
tors play? Interestingly, endostatin (type XVIII collagen)-deficient tumstatin/ mice daily (300 ng) for 8 days in sterile PBS, while only sterile
PBS was injected into the other five Col IV3/tumstatin/ mice. For Figuremice have altered retinal vascular development, but do not ex-
8, eight MMP-9/ and ten wild-type mice were used. Tumstatin proteinhibit accelerated tumor growth (Fukai et al., 2002). Recent experi-
was intravenously injected into four MMP-9/ mice daily (200 ng) for 14ments have shown that thrombospondin-1-deficient mice also
days in sterile PBS when tumors reached 2.0 cm3 and compared to untreated
exhibit increased tumor growth compared to the wild-type mice, wild-type mice starting at same tumor size. LLC tumor bearing mice were
as shown here for Col IV3/tumstatin-deficient mice (Lawler et sacrificed and the tumor and other organs were collected. Some parts of
al., 2001; Rodriguez-Manzaneque et al., 2001). Whether the the collected tissues were frozen in OCT compound and also snap-frozen
in liquid nitrogen, while other parts were fixed in 10% formalin for histologicalantiangiogenic function of endostatin is compensated by Col
analysis.XV or other molecules in the type XVIII collagen-deficient mice
remains to be determined (Eklund et al., 2001; Marneros and
Skin wound healing assay
Olsen, 2001). Excisional (1 cm diameter circular) wounds were made in the epidermis and
In conclusion, this study identifies tumstatin as a physiologi- dermis of five age-and sex-matched Col IV3/tumstatin/, five Col IV3/
cally functional protein domain that circulates in the blood. Tum- tumstatin/, and wild-type mice. Two such skin wounds were created on
each mouse. The longest and shortest diameters of the wounds were mea-statin is not a gene product by itself, but is produced when
sured with a Vernier caliper. Areas were calculated, assuming the woundsMMP-9 cleaves it from Col IV in BM. The physiological level
were approximate ellipses, using the formula [
 X (the longest radius)  (theof tumstatin is dependent on MMP-9, and in its absence, the
shortest radius)]. The mice were sacrificed 3 and 10 days after the wound
physiological concentration in the blood declines, potentially induction. The wounded tissue and the surrounding area were removed,
facilitating pathological angiogenesis and increased growth of fixed in 10% formalin, or snap-frozen in liquid nitrogen and processed for
immunohistochemistry.tumors. The tumor suppressor activity of tumstatin seen at su-
praphysiological concentrations is associated with inhibition of
Liver regeneration studyprotein synthesis, specifically mediated by mTOR, in the endo-
Subtotal hepatectomy was performed using Col IV3/tumstatin/, /, andthelial cells (Maeshima et al., 2002). Based on these results, we
wild-type mice under intraperitoneal ketamine (50 mg/kg) (Parke-Davis) an-
propose that endogenous inhibitors like tumstatin function as esthesia with five mice in each group. Seventy percent of the total liver
tumor suppressors, constituting an additional line of defense mass, including left and middle lobes, was ligated and removed. Ten days
after the operation, BrdU (50 mg/kg) was injected intraperitoneally, 2 hr prioragainst tumor growth in the body, similar to tumor suppressor
to sacrifice of the mice. The livers were removed and some parts weregenes such as p53.
fixed with 4% paraformaldehyde, and other parts were embedded in OCT
compound. BrdU staining was performed using a labeling and detection kitExperimental procedures
according to the manufacturer’s directions (Roche). BrdU-labeling index
was calculated as the number of BrdU-labeled hepatocyte nuclei per 200Cell lines and knockout mice
hepatocyte nuclei, three viewing fields were counted per mouse liver in aLewis lung carcinoma (LLC) cells were grown at 37C in 5% CO2 in DMEM
blinded fashion. The nuclei were stained with 4, 6-diamidino-2-phenylindolewith 10% heat-inactivated fetal bovine serum (FBS) and 5 ng/ml plasmocin
(DAPI) (Vector Laboratories, App Imaging).under sterile tissue culture conditions. Primary mouse lung endothelial cells
(MLEC) were isolated from 10- to 14-week-old 3 integrin/ and wild-type
Matrigel plug assaymice. Briefly, MLEC expressing intercellular adhesion molecule-2 (ICAM-2)
In vivo Matrigel plug assay was performed as previously described (Mae-were enriched using rat anti-mouse ICAM-2 mAb (Pharmingen) conjugated
shima et al., 2000b). Matrigel (BD Biosciences) was mixed with 20 units/ml
to magnetic beads (Dynabeads M-450, Dynal). MLEC were maintained in
of heparin (Pierce), 50 ng/ml of vascular endothelial growth factor (R&D),
40% Ham’s F-12, 40% DME-Low Glucose, 20% FBS supplemented with
and 0.4 M tumstatin or 3 M T7 peptide or 0.5 M endostatin. The Matrigel
heparin, endothelial mitogen (Biomedical Technologies, Inc.), glutamine, 100
mixture was injected subcutaneously into 6 Col IV3/tumstatin/, 6 Col
units/ml of penicillin, and 100 mg/ml of streptomycin.
IV3/tumstatin/, 13 3 integrin/, and 10 integrin/ mice. Six days after
The Col IV3 mice were originally described by Miner et al. and Cosgrove the Matrigel mixture injection, mice were sacrificed. The Matrigel plugs were
et al. (Cosgrove et al., 1996; Miner and Sanes, 1996). The mice were procured removed and fixed with 4% paraformaldehyde or 10% formalin. They were
from Drs. Sanes, Miner, and Cosgrove and also purchased from the Jackson embedded in paraffin, sectioned, and stained with hematoxylin and eosin
laboratories. The mice were backcrossed for more than 15 generations into (HE) or periodic acid-Schiff (PAS). Other parts were embedded in OCT
a C57BL/6 background. The 3 integrin/ mice were originally described compound. Sections were examined using 10 different fields by light micros-
by Hodivala-Dilke et al. (Hodivala-Dilke et al., 1999). The MMP-9/ mice copy, and the numbers of blood vessels at 200 magnifications were
were originally described by Vu et al. (Vu et al., 1998). counted and averaged. All sections were coded and observed by an investi-
gator who was blinded for study protocols.
Production of recombinant tumstatin and synthetic T7 peptide
Recombinant tumstatin was expressed using 293 human embryonic kid- Immunostaining
ney cells as previously described (Maeshima et al., 2000b). Synthetic Immunohistochemical staining was performed as previously described (Ha-
TMPFLFCNVNDCNFASRNDYSYWL-T7 peptide (Maeshima et al., 2001b) mano et al., 2002). Briefly, 4 m frozen sections were fixed in cold (20C)
was synthesized at Tufts University Core Facility and analyzed by mass 100% acetone for 3 min then air dried. They were incubated with various
primary antibodies, i.e., rat anti-mouse CD31 (Pharmingen), rabbit anti-vonspectrophotometric analysis and purified by analytical HPLC.
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Willebrand Factor (vWF) (Dako), rat anti-1 integrin (Pharmingen), and ham- 8-chamber slides. After a 6 hr incubation that allowed endothelial cells to
ster anti-3 integrin (Pharmingen) antibodies at room temperature for 2 hr. attach to the slide, the attached cells were stained with anti-VEGFR2 anti-
Subsequently, they were washed three times in PBS and incubated with body (Santa Cruz). The VEGFR2-positive cells were counted under the fluo-
FITC- or tetramethyl rhodamine-conjugated secondary antibodies (Jackson rescence microscope in 10 fields at a magnification of 200.
ImmunoResearch Laboratories, Inc.) at room temperature for 1 hr. After four
washes with PBS, Vectashield (Vector Laboratories, App Imaging) anti-fade Litter size and developmental index
mounting medium was applied and sections were coverslipped and imaged. For litter size at birth, the average numbers of pups in eight separate litters
For controls, sections were directly incubated with secondary antibodies. delivered from Col IV3/tumstatin/ and age-matched wild-type mating
In each group, the numbers of CD31, vWF, and 1/3 integrin-positive blood pairs were counted. For developmental index, the 6 week survival rates of
vessels were counted in 10–30 fields at 200 or 400 magnifications in a the eight separate litters from both groups were calculated.
blinded fashion.
Statistical analysis
Proliferation assay Statistical differences between two groups were calculated using Student’s
Proliferation assay was performed using [3H]-thymidine incorporation as pre- t test or Welch’s t test. Analysis of variance (ANOVA) was used to determine
viously described (Kamphaus et al., 2000). Briefly, 3 integrin/ and wild- statistical differences among three or more groups. As needed, further analy-
type MLEC (16,000 cells/well) in DMEM containing 5% FBS were plated sis was carried out using t test with Bonferroni correction to identify signifi-
onto 24-well plates. After 24 hr, this medium was replaced with medium cant differences. A p value 0.05 was considered statistically significant.
containing 20% FBS supplemented with 5 ng/ml of bFGF, 10 ng/ml of VEGF,
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